Clinical Trials on Neovascularization, Choroidal in India

Total 11 results

L.V. Prasad Eye Institute
Pfizer

Withdrawn

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia (INGECT)

Myopic Choroidal Neovascular Membrane

India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

China, India, Thailand, Hong Kong, Korea, Republic of, Philippines
Novartis Pharmaceuticals

Completed

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Age-related Macular Degeneration | Choroidal Neovascularization

Korea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
Quark Pharmaceuticals
Pfizer

Completed

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study). (MONET)

Age Related Macular Degeneration

Spain, Korea, Republic of, Turkey, Taiwan, United States, Israel, Austria, Philippines, Denmark, Hong Kong, India
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Pathological Myopia

Germany, India, Japan, Turkey, Austria, Switzerland, Italy, Lithuania, Hungary, France, Slovakia, United Kingdom, Korea, Republic of, Portugal, Hong Kong, Canada, Singapore, Spain, Latvia, Poland
EyePoint Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis

Panuveitis | Posterior Uveitis | Intermediate Uveitis

India
Clearside Biomedical, Inc.

Completed

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

Uveitis, Anterior | Panuveitis | Uveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, India
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

Posterior Uveitis | Intermediate Uveitis

France, United Kingdom, United States, Spain, Poland, India, South Africa, Korea, Republic of, Canada, Czech Republic, Australia, Germany, Israel, Switzerland, Portugal, Austria, Brazil, Greece
Lux Biosciences, Inc.

Completed

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
Lux Biosciences, Inc.

Completed

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis (LUMINATE)

Panuveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, United Kingdom, Canada, Germany, Austria, France, India
Clearside Biomedical, Inc.

Completed

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis (PEACHTREE)

Uveitis, Anterior | Panuveitis | Uveitis | Uveitis, Posterior | Uveitis, Intermediate

United States, Israel, India

Clinical Trials on Neovascularization, Choroidal in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations